Bladder cancer trial halted early: did adding immunotherapy help?
NCT ID NCT03324282
First seen May 22, 2026 · Last updated Jun 22, 2026 · Updated 5 times
Summary
This study tested whether adding the immunotherapy drug avelumab to standard chemotherapy (gemcitabine and cisplatin) works better than chemotherapy alone for people with advanced bladder cancer. The trial planned to enroll 65 patients but was terminated early, so we have limited information. The main goals were to see if the combination shrinks tumors more and to check for severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU de Besançon
Besançon, France
-
CHU de Bordeaux
Bordeaux, France
-
CHU de Poitiers
Poitiers, France
-
CHU de Strasbourg
Strasbourg, France
-
Centre François Baclesse
Caen, France
-
Centre Léon Bérard
Lyon, France
-
Hôpital Européen Georges-Pompidou, AP-HP
Paris, France
-
Hôpital Saint-Louis, AP-HP
Paris, France
-
Institut Bergonié
Bordeaux, France
-
Institut Gustave Roussy
Villejuif, France
-
Institut Paoli Calmettes
Marseille, France
-
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France
-
Institut de cancérologie de l'Ouest - René Gauducheau
Nantes, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avelumab (an immunotherapy drug) combined with gemcitabine and cisplatin (standard chemotherapy)
What this could lead to
If successful, this combination could improve tumor shrinkage and delay cancer progression in advanced bladder cancer patients.
What could go wrong
The trial was terminated early, so we have limited data on effectiveness and safety. Immunotherapy can cause immune-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.